SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas

详细信息    查看全文

• 作者：Yu-An Zhang^a ; ⁱ ; ¹ ; Yunyun Zhou^b ; ^c ; ¹ ; Xin Luo^d ; Kai Song^e ; Xiaotu Ma^f ; Adwait Sathe^g ; Luc Girard^a ; Guanghua Xiao^b ; ^d ; ^h ; Adi F Gazdar^a ; ^h ; ⁱ ; ^{adi.gazdar@utsouthwestern.edu}
• 关键词：Gliomas ; Astrocytomas ; Oligodendrogliomas ; SHOX2 biomarker ; IDH mutation ; Prognosis
• 刊名：EBioMedicine
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：13
• 期：Complete
• 页码：80-89
• 全文大小：1779 K
• 卷排序：13

文摘

SHOX2 is a potent independent prognostic indicator for grade II and III diffuse gliomas. SHOX2 in combination with IDH has the potential to identify important diffuese gliomas subsets with significantly better survivals. SHOX2 in combination with other markers is potentially useful for identifying distinct prognostic subsets of diffuse gliomas.Diffuse glioma brain tumors (gliomas encompassing astrocytomas and oligodedrogliomas, grades II and III), have highly variable, difficult to predict clinical courses and a number of specific alterations have been identified that have prognostic or therapeutic implications, whether as single markers or in various combinations. The use of mutation status of the isocitrate dehydrogenase (IDH) enzyme genes has been demonstrated to be a potent prognostic marker greatly improving survival prognosis. SHOX2 methylation was suggested to be associated with lung and breast cancers. In this study we assessed SHOX2 gene methylation and expression as independent markers for diffuse gliomas survival prognosis, by multiple statistical survival analyses of multiple genome-wide datasets. We have identified that SHOX2 is a potent independent prognostic marker, both by itself and in combination with other markers (IDH mutation status, 1p/19q codeltion, ATRX mutation, nestin or TERT expression and MGMT methylation), and potentially useful for refining the molecular classification of diffuse gliomas, and for distinguishing clinically distinct prognostic subgroups of gliomas patients for better therapy selection.